Tirzepatid

Tirzepatide — GLP-1 / GIP Dual Agonist Research Peptide

Tirzepatide is a synthetic research peptide developed by Eli Lilly that activates two different gut-hormone receptors at once: GLP-1 (the same receptor semaglutide hits, behind Ozempic and Wegovy) and GIP (glucose-dependent insulinotropic polypeptide). It’s the active molecule in Mounjaro and Zepbound and was the first dual incretin agonist engineered for once-weekly administration. Because it adds GIP to the GLP-1 mechanism that semaglutide already established, tirzepatide is the most common reference compound for dual-agonist research and the direct precursor to Lilly’s triple agonist, retatrutide.

Why Dual Agonism Matters

GLP-1 on its own addresses only half of the gut-hormone signal the body releases after a meal. GIP contributes the other half: it amplifies insulin secretion, acts on adipose (fat) tissue, and appears to reduce some of the nausea signaling that comes from GLP-1 in isolation. By combining both receptor activities in a single molecule, tirzepatide lets researchers study the two signals together rather than running them as separate experiments.

Tirzepatide vs Semaglutide vs Retatrutide

All three peptides come from the same GLP-1 research lineage but target different receptor combinations.

The practical research distinction: tirzepatide added GIP to what semaglutide was already doing, and retatrutide added glucagon on top of that. Direct head-to-head data (SURMOUNT-5, published 2024) showed tirzepatide produced larger body-composition endpoints than semaglutide over 72 weeks.

Forschungsanwendungen

Tirzepatide is used in studies examining:

• Body-composition changes under sustained dual-incretin stimulation
• How the added GIP signal changes glucose and insulin dynamics relative to GLP-1-only agonists
• Appetite and satiety models
• Cardiovascular and metabolic markers in the SURMOUNT and SURPASS trial frameworks
• Dose-response characterization across published trial doses (5, 10, 15mg)
• Reference comparisons against semaglutide (single agonist) and retatrutide (triple agonist)

Technische Daten

Rekonstitution

Tirzepatide arrives as a freeze-dried powder and has to be mixed with bacteriostatic water before use. The math is simple:

Gesamtmenge in mg im Fläschchen ÷ hinzugefügte Wassermenge in ml = mg pro ml

Example: a 10mg vial + 2mL of bacteriostatic water = 5mg per mL. A 60mg vial + 3mL = 20mg per mL.

Nach der Zubereitung bei 2–8 °C lagern und innerhalb von 28–30 Tagen verbrauchen.

Anmerkungen zum Protokoll

The following values are reference points extracted from published tirzepatide clinical and preclinical studies – not instructions. Because tirzepatide is active at two receptors, gradual dose escalation is standard throughout the literature and allows researchers to characterize the dose-response curve.

• Starting doses reported in the literature: 2.5mg per administration
• Escalation pattern observed: Step up every 4 weeks through 5mg → 7.5mg → 10mg → 12.5mg → 15mg
• Administration frequency in published trials: Once weekly
• Study durations reported: 12-20 weeks for metabolic endpoints; 72 weeks in SURMOUNT-1 (body composition); 52 weeks in the SURPASS glycemic trials

Common Questions About Tirzepatide Research

Is tirzepatide the same as Ozempic?

No. Ozempic’s active ingredient is semaglutide, which activates one receptor (GLP-1). Tirzepatide activates two receptors (GLP-1 and GIP) and is the active ingredient in Mounjaro and Zepbound. They come from different manufacturers – semaglutide from Novo Nordisk, tirzepatide from Eli Lilly.

What is the difference between tirzepatide and retatrutide?

Tirzepatide activates GLP-1 and GIP. Retatrutide activates those same two receptors plus glucagon, making it a triple agonist. Retatrutide is still in Phase 3 clinical trials; tirzepatide is already commercialized as Mounjaro and Zepbound. In terms of published outcomes, retatrutide has reported larger body-composition endpoints in Phase 2 than tirzepatide has in equivalent-length studies, though direct head-to-head trials are still ongoing.

What does tirzepatide do in metabolic studies?

It activates GLP-1 and GIP receptors simultaneously. Together these receptors regulate glucose-dependent insulin release, glucagon suppression, gastric emptying, appetite signaling in the hypothalamus, and adipose-tissue metabolism. Study endpoints most commonly tracked are HbA1c, fasting glucose, body composition, and ad-libitum caloric intake.

Is tirzepatide FDA approved?

The brand-name formulations (Mounjaro for type 2 diabetes, Zepbound for weight management) are FDA approved for specific clinical indications. Research-grade tirzepatide sold by WWP is not a branded drug product and is not approved or intended for human consumption. Every vial is labeled and sold strictly for laboratory and research use only.

How is tirzepatide stored?

Ungeöffnete Fläschchen werden bei 2–8 °C (Kühlschranktemperatur) gelagert und sind mindestens 12 Monate lang haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.